SCARNA14: A Potential Drug Target and Biomarker (G692149)

Target Name: SCARNA14

NCBI ID: G692149

SCARNA14

Other Name(s): small Cajal body-specific RNA 14 | Small Cajal body-specific RNA 14 | U100

SCARNA14: A Potential Drug Target and Biomarker

Small Cajal body-specific RNA 14 (SCARNA14) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. SCARNA14 is a small RNA molecule that is expressed in the brain and is involved in various cellular processes. The discovery of SCARNA14 as a potential drug target and biomarker has significant implications for the development of new treatments for neurological disorders.

The Cajal body is a region of the brain that is responsible for the control of movement and balance. The Cajal body is composed of several smaller regions, including the diencephalon, the cerebellum, and the cerebrum. SCARNA14 is a molecule that is expressed in the cerebellum and is involved in the regulation of movement and balance.

SCARNA14 is a small RNA molecule that is expressed in the brain and is involved in various cellular processes. It is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. SCARNA14 is a small RNA molecule that is expressed in the brain and is involved in the regulation of movement and balance.

Studies have shown that SCARNA14 is involved in the regulation of several cellular processes, including cell division, cell growth, and cell survival. It is also involved in the regulation of neural circuits, which are responsible for the transmission of signals between neurons.

In addition to its role in cellular processes, SCARNA14 is also involved in the regulation of the nervous system. Studies have shown that SCARNA14 is involved in the regulation of the brain stem, which is responsible for the control of essential functions such as breathing, heart rate, and digestion.

The potential drug target for SCARNA14 is the regulation of movement and balance. SCARNA14 is involved in the regulation of the nervous system, which is responsible for the control of movement and balance.

The potential biomarker for SCARNA14 is the regulation of movement and balance. SCARNA14 is involved in the regulation of the nervous system, which is responsible for the control of movement and balance.

SCARNA14 has been shown to play a role in the development of several neurological disorders, including Parkinson's disease and balance disorders. Studies have shown that mice that have been genetically modified to lack SCARNA14 have experienced improved movement and balance.

In addition to its potential role in the treatment of neurological disorders, SCARNA14 has also been shown to have potential as a drug target. The regulation of movement and balance is a critical function for many individuals, and the development of new treatments for movement and balance disorders could have a significant impact on the quality of life for those individuals.

In conclusion, SCARNA14 is a small RNA molecule that is expressed in the brain and is involved in various cellular processes. The discovery of SCARNA14 as a potential drug target and biomarker has significant implications for the development of new treatments for neurological disorders. Further research is needed to fully understand the role of SCARNA14 in the regulation of movement and balance.

Protein Name: Small Cajal Body-specific RNA 14

The "SCARNA14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCARNA14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets